Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience has launched a new human pilot study to evaluate the oral administration of DehydraTECH-processed tirzepatide, a drug currently only available via injection and expected to generate substantial revenue. The study aims to assess the drug’s tolerability, blood absorption, and glucose control in volunteers and follows successful previous studies that showed improved outcomes with another diabetes medication processed with Lexaria’s DehydraTECH technology.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.